Science & Innovation
The MedRing
as a platform
is built upon market needs, medical science, high tech innovations and clinical studies.
The MedRing as a platform has been developed, tested and upgraded ever since 2016. Starting point was general knowledge about vaginal absorption of drugs, the positive results of the vaginal rings for contraconception and need for new reliable, personalized drug administration, made possible by emerging technology. Eventually, the platform offers great opportunities for innovative treatments, monitoring and insight for women’s health.
Following the first prototypes several tests and studies were executed by LiGalli in cooperation with renowned institutes like, CHDR, University of Leiden, Maxima Medical Center. This overview is carefully selected by LiGalli to give a clear view about the possibilities of the MedRing. It contains a small selection of our literature of important studies, articles and insights. If you are intrigued and would like to learn more, more please contact us.
Literature
01
The vagina as a route for drug delivery: a review; Sushma Srikrishna & Linda Cardozo; Int Urogynecol J (2013) 24:537–543
Vaginal administration allows nondaily, low, continuous dosing, which results in stable drug levels and may, in turn, achieve a lower incidence of side effects and improve patient compliance”.
02
Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing®) Devorah R Wieder Lynn Pattimakiel; International Journal of Women’s Health (2010) 2 401–409
Overall, the contraceptive vaginal ring appears to be very effective, with a favorable side-effect profile, and is highly acceptable to most patients.
03
Bypass of the first pass effect allows for greater bioavailability, lower dosing with accompanying less side effects and less drug-drug interference.
04
Vaginal ring acceptability: A systematic review and meta-analysis of vaginal ring experiences from around the world: Kathleen Ridgeway et al; Contraception 106 (2022) 16–
Women who used vaginal rings reported they were acceptable across indications geographic regions and indications.
Proof of concept
The MedRing: A revolutionary Intravaginal Drug Administration System
Vaginal administration
- Low dosage
- Less side effects
- High compliance
- Long term administration possibilities
Complex and precise administration
- 28 days
- Up to 6 deliveries per day
- Flexible scheduling
- Noctural deliveries
Monitoring and data collection
- Temperature monitoring
- Treatment insights
- Personal preferences
The MedRing introduces an innovative method for intravaginal drug administration. Due to its rich vascularization, the vaginal route provides an effective means for rapid systemic absorption while bypassing the hepatic first-pass metabolism associated with oral administration. By bypassing the first-pass metabolism the MedRing can increase bioavailability of drugs versus oral administration. This can lead to lower doses and less side-effects, as we have seen in our trials with oxybutynin.
The MedRing is anatomically designed to achieve optimal fit within the vaginal cavity, ensuring direct and continuous contact with the vaginal mucosa. This facilitates absorption of the active pharmaceutical ingredient, accompanied by the intuitive smartphone Companion App, the MedRing empowers users to personalize dosing schedules and monitor therapy effectiveness. This makes it the first user-customizable, controlled intravaginal drug delivery platform, ushering in a new era of precision medicine for women’s health.
Literature
April 2025
Overall, the contraceptive vaginal ring appears to be very effective, with a favorable side-effect profile, and is highly acceptable to most patients.
Dec 2024
Poster presentation at the British Pharmacological Society’s annual conference in Harrogate. By Sophie Peltenburg, Research Physician Gynaecology, and Anouk Meijs, Research Physician Internal Medicine, at Centre for Human Drug Research
“Intravaginal delivery of oxybutynin via the MedRing OAB: a double-blind three-way crossover study comparing intravaginal and oral oxybutynin administration” presenting the outcomes of an important clinical trial with oxybutynin delivered vaginally via LiGalli’s MedRing .The poster showcased valuable outcomes on differentiating PK-characteristics and side-effect profiles in healthy subjects.
Feb 2023
First-in human study to assess the pharmacokinetics, tolerability, and safety of single-dose oxybutynin hydrochloride administered via a microprocessor-controlled intravaginal ring;
Drugdelivery: Willem de Laat et al 2023
The MedRing Controlled vaginal drug administration – First In Human study with Oxybutynin: therapeutic plasma levels combined with lower metabolites as compared to oral administration.
Get in touch
Office
Leiden Bio Science Park – BioPartner 1
Address
J.H. Oortweg 21
2333 CH Leiden
The Netherlands